44 related articles for article (PubMed ID: 26505795)
21. C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells.
Zhu X; Du X; Deng X; Yi H; Cui S; Liu W; Shen A; Cui Z
Biochem Biophys Res Commun; 2014 Sep; 452(1):72-8. PubMed ID: 25152399
[TBL] [Abstract][Full Text] [Related]
22. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
23. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
24. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
25. Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity.
Zhao X; Sun B; Zhang J; Zhang R; Zhang Q
Biochem Biophys Res Commun; 2016 Oct; 479(2):166-172. PubMed ID: 27562715
[TBL] [Abstract][Full Text] [Related]
26. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
27. Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic.
Kester M; Bassler J; Fox TE; Carter CJ; Davidson JA; Parette MR
Biol Chem; 2015 Jun; 396(6-7):737-47. PubMed ID: 25838296
[TBL] [Abstract][Full Text] [Related]
28. Emerging Anticancer Potentials of Selenium on Osteosarcoma.
Pang KL; Chin KY
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731474
[TBL] [Abstract][Full Text] [Related]
29. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
30. Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes.
Liang W; Dong Y; Shao R; Zhang S; Wu X; Huang X; Sun B; Zeng B; Zhao J
J Drug Target; 2022 Jun; 30(5):463-475. PubMed ID: 34962448
[TBL] [Abstract][Full Text] [Related]
31. Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma.
Dana PM; Sadoughi F; Asemi Z; Yousefi B
Curr Med Chem; 2022; 29(25):4436-4444. PubMed ID: 35139778
[TBL] [Abstract][Full Text] [Related]
32. Innovative approaches for treatment of osteosarcoma.
Rothzerg E; Pfaff AL; Koks S
Exp Biol Med (Maywood); 2022 Feb; 247(4):310-316. PubMed ID: 35043695
[TBL] [Abstract][Full Text] [Related]
33. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach.
Santos A; Domingues C; Jarak I; Veiga F; Figueiras A
Eur J Pharm Biopharm; 2022 Jan; 170():91-111. PubMed ID: 34896571
[TBL] [Abstract][Full Text] [Related]
34. Ceramide-based therapeutics for the treatment of cancer.
Barth BM; Cabot MC; Kester M
Anticancer Agents Med Chem; 2011 Nov; 11(9):911-9. PubMed ID: 21707481
[TBL] [Abstract][Full Text] [Related]
35. Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment.
Ali Gumustas S; Isyar M; Topuk S; Yilmaz I; Oznam K; Onay T; Ofluoglu O; Mahirogullari M
Curr Pharm Biotechnol; 2016; 17(10):866-72. PubMed ID: 27194356
[TBL] [Abstract][Full Text] [Related]
36. Inorganic phosphate as a signaling molecule: a potential strategy in osteosarcoma treatment.
Spina A; Sorvillo L; Esposito A; Borgia A; Sapio L; Naviglio S
Curr Pharm Des; 2013; 19(30):5394-403. PubMed ID: 23394088
[TBL] [Abstract][Full Text] [Related]
37. Delivery systems of ceramide in targeted cancer therapy: ceramide alone or in combination with other anti-tumor agents.
Ma YY; Mou XZ; Ding YH; Zou H; Huang DS
Expert Opin Drug Deliv; 2016 Oct; 13(10):1397-406. PubMed ID: 27168034
[TBL] [Abstract][Full Text] [Related]
38. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
